Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

224 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402.
Nogami N, Hotta K, Segawa Y, Takigawa N, Hosokawa S, Oze I, Fujii M, Ichihara E, Shibayama T, Tada A, Hamada N, Uno M, Tamaoki A, Kuyama S, Ikeda G, Osawa M, Takata S, Tabata M, Tanimoto M, Kiura K. Nogami N, et al. Among authors: oze i. Acta Oncol. 2012 Jul;51(6):768-73. doi: 10.3109/0284186X.2011.648342. Epub 2012 Jan 27. Acta Oncol. 2012. PMID: 22283472 Clinical Trial.
Impact of multiple alcohol dehydrogenase gene polymorphisms on risk of upper aerodigestive tract cancers in a Japanese population.
Oze I, Matsuo K, Suzuki T, Kawase T, Watanabe M, Hiraki A, Ito H, Hosono S, Ozawa T, Hatooka S, Yatabe Y, Hasegawa Y, Shinoda M, Kiura K, Tajima K, Tanimoto M, Tanaka H. Oze I, et al. Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):3097-102. doi: 10.1158/1055-9965.EPI-09-0499. Epub 2009 Oct 27. Cancer Epidemiol Biomarkers Prev. 2009. PMID: 19861527
[Efficacy and safety of aprepitant in patients with breast cancer].
Tagashira H, Matsuhisa T, Oze I, Kiyoto S, Takahashi M, Hara F, Takabatake D, Takashima S, Aogi K, Osumi S, Eguchi H. Tagashira H, et al. Among authors: oze i. Gan To Kagaku Ryoho. 2011 Aug;38(8):1307-11. Gan To Kagaku Ryoho. 2011. PMID: 21829069 Japanese.
Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience.
Kato Y, Hotta K, Takigawa N, Nogami N, Kozuki T, Sato A, Ichihara E, Kudo K, Oze I, Tabata M, Shinkai T, Tanimoto M, Kiura K. Kato Y, et al. Among authors: oze i. Cancer Chemother Pharmacol. 2014 May;73(5):943-50. doi: 10.1007/s00280-014-2425-9. Epub 2014 Mar 16. Cancer Chemother Pharmacol. 2014. PMID: 24633759
A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501.
Nogami N, Takigawa N, Hotta K, Segawa Y, Kato Y, Kozuki T, Oze I, Kishino D, Aoe K, Ueoka H, Kuyama S, Harita S, Okada T, Hosokawa S, Inoue K, Gemba K, Shibayama T, Tabata M, Takemoto M, Kanazawa S, Tanimoto M, Kiura K. Nogami N, et al. Among authors: oze i. Lung Cancer. 2015 Feb;87(2):141-7. doi: 10.1016/j.lungcan.2014.11.001. Epub 2014 Nov 8. Lung Cancer. 2015. PMID: 25534129 Clinical Trial.
224 results